↓ Skip to main content

Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia

Overview of attention for article published in Antimicrobial Agents and Chemotherapy, January 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

blogs
1 blog
policy
1 policy source
twitter
5 X users
video
1 YouTube creator

Citations

dimensions_citation
175 Dimensions

Readers on

mendeley
131 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia
Published in
Antimicrobial Agents and Chemotherapy, January 2013
DOI 10.1128/aac.01485-12
Pubmed ID
Authors

Natasha E. Holmes, John D. Turnidge, Wendy J. Munckhof, J. Owen Robinson, Tony M. Korman, Matthew V. N. O'Sullivan, Tara L. Anderson, Sally A. Roberts, Sanchia J. C. Warren, Wei Gao, Benjamin P. Howden, Paul D. R. Johnson

Abstract

A ratio of the vancomycin area under the concentration-time curve to the MIC (AUC/MIC) of ≥ 400 has been associated with clinical success when treating Staphylococcus aureus pneumonia, and this target was recommended by recently published vancomycin therapeutic monitoring consensus guidelines for treating all serious S. aureus infections. Here, vancomycin serum trough levels and vancomycin AUC/MIC were evaluated in a "real-world" context by following a cohort of 182 patients with S. aureus bacteremia (SAB) and analyzing these parameters within the critical first 96 h of vancomycin therapy. The median vancomycin trough level at this time point was 19.5 mg/liter. There was a significant difference in vancomycin AUC/MIC when using broth microdilution (BMD) compared with Etest MIC (medians of 436.1 and 271.5, respectively; P < 0.001). Obtaining the recommended vancomycin target AUC/MIC of ≥ 400 using BMD was not associated with lower 30-day all-cause or attributable mortality from SAB (P = 0.132 and P = 0.273, respectively). However, an alternative vancomycin AUC/MIC of >373, derived using classification and regression tree analysis, was associated with reduced mortality (P = 0.043) and remained significant in a multivariable model. This study demonstrated that we obtained vancomycin trough levels in the target therapeutic range early during the course of therapy and that obtaining a higher vancomycin AUC/MIC (in this case, >373) within 96 h was associated with reduced mortality. The MIC test method has a significant impact on vancomycin AUC/MIC estimation. Clinicians should be aware that the current target AUC/MIC of ≥ 400 was derived using the reference BMD method, so adjustments to this target need to be made when calculating AUC/MIC ratio using other MIC testing methods.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 131 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
Netherlands 1 <1%
Switzerland 1 <1%
Unknown 128 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 21 16%
Student > Ph. D. Student 20 15%
Other 17 13%
Student > Bachelor 15 11%
Student > Doctoral Student 11 8%
Other 23 18%
Unknown 24 18%
Readers by discipline Count As %
Medicine and Dentistry 51 39%
Pharmacology, Toxicology and Pharmaceutical Science 26 20%
Agricultural and Biological Sciences 7 5%
Biochemistry, Genetics and Molecular Biology 5 4%
Immunology and Microbiology 5 4%
Other 9 7%
Unknown 28 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 April 2024.
All research outputs
#2,502,436
of 25,820,938 outputs
Outputs from Antimicrobial Agents and Chemotherapy
#1,252
of 15,646 outputs
Outputs of similar age
#24,062
of 295,311 outputs
Outputs of similar age from Antimicrobial Agents and Chemotherapy
#9
of 120 outputs
Altmetric has tracked 25,820,938 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 15,646 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 295,311 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 120 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.